Next Article in Journal
Influence of Cigarette Smoke Inhalation on an Autogenous Onlay Bone Graft Area in Rats with Estrogen Deficiency: A Histomorphometric and Immunohistochemistry Study
Previous Article in Journal
Thrombomodulin Regulation of Mitogen-Activated Protein Kinases
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(8), 1853; https://doi.org/10.3390/ijms20081853

SUMOylation in Glioblastoma: A Novel Therapeutic Target

1
Department of Neurosurgery, University of Alabama at Birmingham, 1060 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35223, USA
2
Medical Scientist Training Program, University of Alabama at Birmingham, 1825 University Boulevard, SHEL 121, Birmingham, AL 35294, USA
3
Department of Neurosurgery, University Hospital Frankfurt, Goethe-University, Schleusenweg 2-16, 60528 Frankfurt, Germany
4
Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, Via S. Sofia n. 97, Torre Biologica, 95123 Catania, Italy
5
Division of Neuroradiology, Department of Radiology, University of Alabama at Birmingham, Jefferson Tower N419—619 19th Street South, Birmingham, AL 35223, USA
6
Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Lowder 512, 1600 7th Avenue South, Birmingham, AL 35223, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors jointly supervised this work.
Received: 24 March 2019 / Revised: 11 April 2019 / Accepted: 11 April 2019 / Published: 15 April 2019
  |  
PDF [647 KB, uploaded 15 April 2019]
  |  

Abstract

Protein SUMOylation is a dynamic post-translational modification which is involved in a diverse set of physiologic processes throughout the cell. Of note, SUMOylation also plays a role in the pathobiology of a myriad of cancers, one of which is glioblastoma (GBM). Accordingly, herein, we review core aspects of SUMOylation as it relates to GBM and in so doing highlight putative methods/modalities capable of therapeutically engaging the pathway for treatment of this deadly neoplasm. View Full-Text
Keywords: glioblastoma (GBM); SUMOylation; SUMO1-3; post-translational modifications (PTMs) glioblastoma (GBM); SUMOylation; SUMO1-3; post-translational modifications (PTMs)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fox, B.M.; Janssen, A.; Estevez-Ordonez, D.; Gessler, F.; Vicario, N.; Chagoya, G.; Elsayed, G.; Sotoudeh, H.; Stetler, W.; Friedman, G.K.; Bernstock, J.D. SUMOylation in Glioblastoma: A Novel Therapeutic Target. Int. J. Mol. Sci. 2019, 20, 1853.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top